Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
297.18 +2.16 (+0.73%) 13:34 ET [NASDAQ]
296.65 x 6 298.50 x 3
Realtime by (Cboe BZX)
296.65 x 6 298.50 x 3
Realtime 296.15 +1.13 (+0.38%) 08:14 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
295.36
Day High
310.00
Open 297.84
Previous Close 295.02 295.02
Volume 153,511 153,511
Avg Vol 327,164 327,164
Stochastic %K 28.59% 28.59%
Weighted Alpha +10.34 +10.34
5-Day Change -23.35 (-7.24%) -23.35 (-7.24%)
52-Week Range 189.00 - 377.46 189.00 - 377.46
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,514,039
  • Shares Outstanding, K 22,080
  • Annual Sales, $ 180,130 K
  • Annual Income, $ -465,890 K
  • EBIT $ -498 M
  • EBITDA $ -495 M
  • 60-Month Beta -0.69
  • Price/Sales 36.98
  • Price/Cash Flow N/A
  • Price/Book 8.72

Options Overview Details

View History
  • Implied Volatility 75.28% ( -0.78%)
  • Historical Volatility 40.96%
  • IV Percentile 89%
  • IV Rank 64.45%
  • IV High 93.93% on 10/18/24
  • IV Low 41.48% on 08/19/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 569
  • Volume Avg (30-Day) 569
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 14,141
  • Open Int (30-Day) 18,538

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -3.66
  • Number of Estimates 8
  • High Estimate -2.71
  • Low Estimate -4.91
  • Prior Year -7.38
  • Growth Rate Est. (year over year) +50.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
276.20 +8.24%
on 04/21/25
Period Open: 341.62
350.50 -14.70%
on 03/25/25
-42.65 (-12.48%)
since 03/21/25
3-Month
276.20 +8.24%
on 04/21/25
Period Open: 324.71
377.46 -20.79%
on 02/26/25
-25.74 (-7.93%)
since 01/22/25
52-Week
189.00 +58.19%
on 04/26/24
Period Open: 213.49
377.46 -20.79%
on 02/26/25
+85.48 (+40.04%)
since 04/22/24

Most Recent Stories

More News
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025

MDGL : 297.18 (+0.73%)
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer

MDGL : 297.18 (+0.73%)
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

MDGL : 297.18 (+0.73%)
Why Madrigal Pharmaceuticals Stock Is Soaring Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and...

MDGL : 297.18 (+0.73%)
Madrigal: Q4 Earnings Snapshot

Madrigal: Q4 Earnings Snapshot

MDGL : 297.18 (+0.73%)
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

MDGL : 297.18 (+0.73%)
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

MDGL : 297.18 (+0.73%)
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

MDGL : 297.18 (+0.73%)
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

MDGL : 297.18 (+0.73%)
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week

An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (NASDAQ: MDGL) stock out of the doldrums over the past few trading...

MDGL : 297.18 (+0.73%)
GS : 515.15 (+2.75%)
Why Madrigal Pharmaceuticals Stock Is Sinking Today

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full-year 2024...

MDGL : 297.18 (+0.73%)
Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

MDGL : 297.18 (+0.73%)
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MDGL : 297.18 (+0.73%)
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

NVO : 59.38 (+1.80%)
MDGL : 297.18 (+0.73%)
LLY : 820.34 (+0.28%)
Insider Sale: Director at $MDGL (MDGL) Sells 520 Shares

FRED B CRAVES, a director at $MDGL ($MDGL), sold 520 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.5% of their shares....

MDGL : 297.18 (+0.73%)
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst

Ken Griffin started the Citadel hedge fund in 1990. It's become so successful that his net worth has risen to a stunning $46 billion.

VKTX : 24.89 (+4.93%)
RILY : 3.08 (+4.41%)
NVO : 59.38 (+1.80%)
MDGL : 297.18 (+0.73%)
LLY : 820.34 (+0.28%)
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move

When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (NASDAQ: MDGL)...

MDGL : 297.18 (+0.73%)
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 62.40 (-0.79%)
TBPH : 9.25 (+1.31%)
MDGL : 297.18 (+0.73%)
LRMR : 2.24 (+11.44%)
CPRX : 22.58 (+2.54%)
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More

There's a bright future ahead for this company.

MDGL : 297.18 (+0.73%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 62.40 (-0.79%)
TBPH : 9.25 (+1.31%)
MDGL : 297.18 (+0.73%)
LRMR : 2.24 (+11.44%)
CPRX : 22.58 (+2.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-' agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia...

See More

Key Turning Points

3rd Resistance Point 329.82
2nd Resistance Point 315.33
1st Resistance Point 305.18
Last Price 297.18
1st Support Level 280.53
2nd Support Level 266.04
3rd Support Level 255.89

See More

52-Week High 377.46
Fibonacci 61.8% 305.47
Last Price 297.18
Fibonacci 50% 283.23
Fibonacci 38.2% 260.99
52-Week Low 189.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro